Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CD19-CD34 CAR transduced T-cells |
Synonyms | |
Therapy Description |
CD19-CD34 CAR transduced T-cells are metabolically enhanced T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and selected for CD34 expression, which potentially induce toxicity in CD19-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CD19-CD34 CAR transduced T-cells | CD19-CD34t Metabolically Programmed CAR T-cells | CD19 Immune Cell Therapy 64 | CD19-CD34 CAR transduced T-cells are metabolically enhanced T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and selected for CD34 expression, which potentially induce toxicity in CD19-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05702853 | Phase Ib/II | CD19-CD34 CAR transduced T-cells Cyclophosphamide + Fludarabine | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | Recruiting | USA | 0 |